The National Institute of Allergy and Infectious Diseases (NIAID) has restructured five HIV/AIDS clinical trials networks for the next seven years, according to a statement by NIAID, which is part of the National Institutes of Health (NIH). Principal investigators and clinical trials units (CTUs) have been selected to create “a broader, more flexible and more collaborative approach,” said Anthony Fauci, MD, director of NIAID. The 37 CTUs oversee 108 clinical research sites in the United States and worldwide. Their total funding is estimated at $225 million in 2014, the first year of operation. The new awards expand research beyond HIV/AIDS to include tuberculosis and hepatitis, the most significant co-infections for people living with or at risk for HIV. The funds will support research into prevention, treatment and cures for each disease.

To read the statement, click here.